To assess whether fragmented iASPP can inhibit p53 and RelA/p65 transcriptional activity, we first used a p53-inducible gene 3 (PIG3) reporter assay in the breast cancer cell line MCF-7, which contains wild-type p53. This evidence concerns the gene TP53 and breast carcinoma.